A compressed tablet for oral administration which comprises: (A) an intragranular component comprising: (i) the alkali metal salt of raltegravir, which is a sodium or potassium salt employed in an amount in a range of from 50 wt.% to 65 wt.% on a free phenol basis; (ii) a first superdisintegrant, employed in an amount in a range of from 5 wt.% to 10 wt.%;; (iii) a binder, employed in an amount in a range of from 2 wt.% to 6 wt.%; (B) an extragranular component comprising: (i) a second superdisintegrant, employed in an amount in a range of from 6 wt.% to 12 wt.%; (ii) a filler, employed in an amount in a range of from 6 wt.% to 25 wt.%; and (iii) a lubricant, employed in an amount in a range of from 1 wt.% to 2.5 wt.%; wherein the total amount of superdisintegrant is in a range of from 10 wt.% to 18 wt.%; and wherein the weight percent of each ingredient in the compressed tablet is based on the total weight of the compressed tablet, with the proviso that the tablet is free of atazanavir or a pharmaceutically acceptable salt thereof. (A) an intragranular component comprising: (i) the alkali metal salt of raltegravir, which is a sodium or potassium salt employed in an amount in a range of from 50 wt.% to 65 wt.% on a free phenol basis; (ii) a first superdisintegrant, employed in an amount in a range of from 5 wt.% to 10 wt.%;; (iii) a binder, employed in an amount in a range of from 2 wt.% to 6 wt.%; (i) the alkali metal salt of raltegravir, which is a sodium or potassium salt employed in an amount in a range of from 50 wt.% to 65 wt.% on a free phenol basis; (ii) a first superdisintegrant, employed in an amount in a range of from 5 wt.% to 10 wt.%;; (iii) a binder, employed in an amount in a range of from 2 wt.% to 6 wt.%; (B) an extragranular component comprising: (i) a second superdisintegrant, employed in an amount in a range of from 6 wt.% to 12 wt.%; (ii) a filler, employed in an amount in a range of from 6 wt.% to 25 wt.%; and (iii) a lubricant, employed in an amount in a range of from 1 wt.% to 2.5 wt.%; wherein the total amount of superdisintegrant is in a range of from 10 wt.% to 18 wt.%; and wherein the weight percent of each ingredient in the compressed tablet is based on the total weight of the compressed tablet, with the proviso that the tablet is free of atazanavir or a pharmaceutically acceptable salt thereof. (i) a second superdisintegrant, employed in an amount in a range of from 6 wt.% to 12 wt.%; (ii) a filler, employed in an amount in a range of from 6 wt.% to 25 wt.%; and (iii) a lubricant, employed in an amount in a range of from 1 wt.% to 2.5 wt.%; wherein the total amount of superdisintegrant is in a range of from 10 wt.% to 18 wt.%; and wherein the weight percent of each ingredient in the compressed tablet is based on the total weight of the compressed tablet, with the proviso that the tablet is free of atazanavir or a pharmaceutically acceptable salt thereof. wherein the total amount of superdisintegrant is in a range of from 10 wt.% to 18 wt.%; and wherein the weight percent of each ingredient in the compressed tablet is based on the total weight of the compressed tablet, with the proviso that the tablet is free of atazanavir or a pharmaceutically acceptable salt thereof. <EOS>